# A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

> **NCT01703572** · PHASE1 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Relapsed or Refractory Lymphoid Malignancies

## Interventions

- **DRUG:** OMP-52M51

## Key facts

- **NCT ID:** NCT01703572
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703572, "A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01703572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*